Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has
been a model for cancer therapy development. Though most patients with CML have a …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

Purpose We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in
Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …

Purpose The introduction of imatinib, a tyrosine kinase inhibitor (TKI), has greatly increased
survival for patients with chronic myeloid leukemia (CML). Conversely, nonadherence to …

Objetivos: Describir los factores que pueden influir en la adherencia a los tratamientos
farmacológicos y las intervenciones que han sido desarrolladas para su mejora. Métodos …

Purpose We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in
chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular …

The treatment of acute promyelocytic leukemia has improved considerably after recognition
of the effectiveness of all-trans-retinoic acid (ATRA), anthracycline-based chemotherapy …

Background Cancer is a disease that mostly affects older adults. Treatment adherence is
crucial to obtain optimal outcomes such as cure or improvement in quality of life. Older …